Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT05572333 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

Start date: November 22, 2022
Phase: Phase 2
Study type: Interventional

The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.

NCT ID: NCT05563701 Completed - Heart Diseases Clinical Trials

Evaluation of the LVivo Image Quality Scoring (IQS)

Start date: September 5, 2022
Phase:
Study type: Observational

The study includes two parts: Part 1: - 100 examinations of patient referred for echo evaluation, containing clips that were acquired from the 4CH apical view were collected retrospectively. Each study includes 10 clips that represent typical user scanning errors - Offline evaluation of the system (by batch processing) shall be performed by comparing the system output to preliminary quality tagging by experienced sonographers Part 2: - Live scans of apical 4CH clips of patients with indication for POCUS examination will be performed by POC physicians - LVivo IQS shall be used (on Lumify) during the scan for patients that meet inclusion criteria until 50 exams will be collected. 3 sec of each scan shall be saved, and Image quality score (IQS) shall be documented - Saved scans shall be reviewed by an expert physician to determine whether they are clinically interpretable

NCT ID: NCT05562843 Completed - COPD ILD Clinical Trials

Autologous Cellular Therapy With PRP-PC in Chronic Lung Diseases: An Observational Study LI-004

PRP-PC
Start date: June 10, 2021
Phase:
Study type: Observational

For this study, cells will be harvested from the patient from the peripheral blood, isolated and concentrated using proprietary Emcyte™ equipment/centrifugation, and then returned to the patient same day via the peripheral circulation. As circulation occurs, the concentrated cells enter the right heart and are then disseminated into the lungs, becoming trapped in the lung's microcirculation. Here, the cells are believed to produce multiple bioactive factors such as cytokines and anti-inflammatory mediators. Several growth factors are released by activated platelets becoming honing cells for healing within the tissue. The exact long-term mechanism of action of PRP-PC in the lungs remains under investigation. Safety studies have proven that autologous treatment is incredibly safe, largely because of the minimal cell manipulation and the autologous nature of the cells. Prior observational studies in this are have shown strong safety profiles as well as strong efficacy in both COPD and ILD.

NCT ID: NCT05553847 Completed - Clinical trials for COPD (Chronic Obstructive Pulmonary Disease)

Automated Oxygen Titration in Daily Life in Patients With COPD on Home Oxygen

DaiLiHOT_1
Start date: October 30, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of automated oxygen titration compared to the usual fixed dose oxygen on the patient's ability to perform activities of daily living.

NCT ID: NCT05538975 Completed - COPD Clinical Trials

Effect of Self-directed and Supervised Pulmonary Rehabilitation Approach on Cough and Sputum.

Start date: February 23, 2022
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD)is a multifactorial, progressive chronic lung disease that causes airflow restriction. Study was conducted To Compare the effects of supervised and self-directed pulmonary rehabilitation on cough and sputum expectoration in patients of chronic obstructive pulmonary disease.

NCT ID: NCT05535972 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Start date: October 14, 2022
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD. The secondary objective is to evaluate the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with symptomatic COPD.

NCT ID: NCT05531539 Completed - Clinical trials for Chronic Lung Disease

Evaluation of Wearable Vest for Lung Monitoring

WELMO
Start date: January 10, 2022
Phase: N/A
Study type: Interventional

This was the pilot study of the EU funded research and innovation project WELMO (Wearable Electronics for Effective Lung Monitoring) -Grant agreement number: 825572. The clinical trial involved patients suffering from a variety of respiratory pathological conditions and examined the ease-of-use and efficacy of the WELMO system, comprising a sensors vest for thorax auscultation and recording of Electric Impedance Tomography (EIT) signals and transmitting those on the cloud for review by physicians. The study recruited and briefly monitored 27 patients who underwent brief training and subsequent wearing of the sensors vest for 15-20 minutes, after manual auscultation, spirometry and oximetry. The collected data were transmitted wirelessly to a tablet and then securely to the cloud for review by attending physicians. The usability of the system, the quality of the obtained signals and the validity of the results were evaluated.

NCT ID: NCT05523180 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study aims to evaluate the impact of a specific oral probiotic blend on the quality of life of adults with respiratory conditions.

NCT ID: NCT05504993 Completed - Clinical trials for Comorbidities and Coexisting Conditions

Are Comorbidities Related to Frequent Severe Exacerbations of AECOPD

Start date: January 1, 2018
Phase:
Study type: Observational

INTRODUCTION: Relationship between comorbidities and COPD is two-sided. While the number of comorbidities increasing, the frequency of acute exacerbations of COPD (AECOPD) is increasing, too. Comorbidity indexes can be used for recognition of comorbidities while managing COPD patients. In the present study, it is aimed to compare comorbidity indexes such as Charlson Comorbidity Index, COMCOLD and COTE in the matter of exacerbation frequency. METHOD: Subjects hospitalized for AECOPD, admitted to the study. Exacerbation severity, frequency, further exacerbations for a 1-year period in the follow-up period and CCI, COMCOLD and COTE scores were recorded. High and low comorbidity groups were compared for AECOPD frequency, severity, and further exacerbations.

NCT ID: NCT05495256 Completed - Asthma Clinical Trials

Monitoring Metered Dose Inhalation (MDI) Volume and Timing With a Respimetrix Device in Obstructive Lung Disease.

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

To Determine whether use of the Respimetrix flow test device a) can determine "good" versus "poor" inhaler techniques, and b) the effects of the inhaler training on technique.